January | February | March | April | Pending COMPLETED MERGERS AND ACQUISITIONS - April 2013 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details Obagi Medical Products Inc. Valeant Pharmaceuticals International Inc. 4/26/13 4/26/13 $352.8 Valeant acquired Obagi for $24 per share in cash, with a total of 14.7M shares tendered Trillium Therapeutics Inc. Stem Cell Therapeutics Corp. 2/11/13 4/11/13 $2.85
January | February | March | April | May | May - 2013 Biotech Company Pharma Company Type/Product Area Terms/Details Abide Therapeutics Inc. Merck & Co. Inc. Deal focusing on Type II diabetes by way of small molecules targeting members of the serine hydrolase enzyme family Abide gets an up-front payment and research funding, plus possible milestone payments of up to $430M; Merck gains worldwide commercialization rights and will pay royalties to Abide Actavis Inc. Valeant
Public Companies | Private Companies PUBLIC COMPANIES - May 2013 Company Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Arrowhead Research Corp. Private placement 14.3S $36 Celator Pharmaceuticals Inc. Private placement of common stock and warrants 10.43S and W $32.5 Galapagos NV Private placement 2.7S E53.9 ($70.7) Innovus Pharmaceuticals Inc. Investment N/A $0.5 Omeros Corp. Registered direct offering 3.9S $16
Follow-on Offerings FOLLOW-ON OFFERINGS - May 2013 Company Date Filed Date Comm. Shares/Units (M) Price Gross (M) Discovery Laboratories Inc. (DSCO) 6/21/11 5/13/13 9.5S $1.50 $14.25 iCo Therapeutics Inc. (TSXV:ICO) 7/3/12 5/9/13 9.17U C$0.35 ($0.35) C$3.2 ($3.15) Idera Pharmaceuticals Inc. (IDRA) 5/2/13 5/2/13 17.5S and W for 17.5S and 15.8S $0.50 and $0.49 $16.5 Isis Pharmaceuticals Inc. (ISIS) 5/7/13 5/9/13 9S $19 $171 FOLLOW
January | February | March | April | May | May - 2013 Company Company Type/Product Area Terms/Details Algeta ASA Lumiphore Inc. Global agreement on incorporation of Lumiphore's Lumi4 complexes in Algeta's targeted radiotherapeutics and companion diagnostics Algeta has an option to the exclusive rights to incorporate Lumi4 isophthalamide chelation technology into future targeted radiopharmaceutical therapeutics for cancer AmorChem InflammatorRx Inc. Research collaboration
January | February | March | April | May | June | July | August | September | October | November | December | December - 2012 Company Company Type/Product Area Terms/Details Amarantus BioScience Inc. Power3 Medical Products Inc. Deal to buy all of the intellectual property assets from Power3, giving Amarantus the ability to acquire IP for the diagnosis of multiple neurodegenerative diseases and oncology Amarantus is paying $40,000, and the deal includes five patents and 20
Commenced Trading | Filed and Pending COMMENCED TRADING - December 2012 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) No initial public offerings were completed in December. COMMENCED TRADING - November 2012 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) No initial public offerings were completed in November. COMMENCED TRADING - October 2012 INITIAL OFFERINGS
Public Companies | Private Companies PUBLIC COMPANIES - December 2012 Company Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Amarin Corp. plc Investment N/A $100 Arno Therapeutics Inc. Private placements of senior convertible debentures and warrants N/A $2.15 Cel-Sci Corp. Registered direct offering 35S and W for 26.25S $10.5 Cyclacel Pharmaceuticals Inc. Common stock purchase agreement N/A $1 GeneNews Ltd. Private
January | February | March | April | May | June | July | August | September | October | November | December | December - 2012 Biotech Company Pharma Company Type/Product Area Terms/Details AIMM Therapeutics NV Cosmo Pharmaceuticals SpA Strategic partnership to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma Cosmo will formulate human monoclonal antibodies generated by AIMM in an extended-release form exploiting its MMX
January | February | March | April | May | June | July | August | September | October | November | December COMPLETED MERGERS AND ACQUISITIONS - December 2012 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details DeCode Genetics Amgen Inc. 12/11/12 12/11/12 $415 Amgen is acquiring DeCode for $415M DUSA Pharmaceuticals Inc. Sun Pharmaceutical Industries Ltd. 11/9/12 12/20/12 $230 A 100% subsidiary of Sun
January | February | March | April | May | June | July | August | September | October | November | December COMPLETED MERGERS AND ACQUISITIONS - December 2011 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details Adagio Pharmaceuticals Ltd. Cynapsus Therapeutics Inc. 8/18/11 12/28/11 $1.3 Cynapsus acquired Adagio with 26M common shares with a deemed value of 5 cents per share Adolor Corp. Cubist Pharmaceuticals Inc
January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Biotech Company Pharma Company Type/Product Area Terms/Details Akorn Inc. H. Lundbeck A/S Akorn's subsidiary, Oak Pharmaceuticals, acquired three off-patent, branded, hospital-based injectables Akorn will make an up-front payment of $45M and a subsequent milestone payment of $15M in cash after three years Amgen Inc. Watson Pharmaceuticals Inc. Deal to develop
January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Company Company Type/Product Area Terms/Details Ampio Pharmaceuticals Inc. Undisclosed party Deal to acquire rights to a patented orally disintegrating tablet drug delivery technology for use with Zertane, its candidate for premature ejaculation Financial terms were not disclosed AtheroNova Inc. OOO CardioNova (Russian subsidiary of Maxwell Biotech
Public Companies | Private Companies PUBLIC COMPANIES - December 2011 Company (Symbol) Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Allon Therapeutics Inc. Investment N/A $5.44 Ampio Pharmaceuticals Inc. Registered direct offering 2S $9.5 ARCA Biopharma Inc. Private placement of common stock and warrants 1.67U $1.75 Cell Therapeutics Inc. Registered direct offering 17.4S and W for 6.96S $8.8 Celsion Corp. Private
Commenced Trading COMMENCED TRADING - December 2011 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) No initial public offerings have commenced in December. COMMENCED TRADING - November 2011 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) Clovis Oncology Inc. (CLVS) 6/23/11 11/15/11 10.7S $13 22.4 $139.1 NewLink Genetics Corp. (NLNK) 12/21/10 11/11/11
January | February | March | April | May | June | July | August | September | October | November | December | December - 2010 Company Company Type/Product Area Terms/Details Adimab Inc. Genentech Inc. (NYSE:DNA), Human Genome Sciences Inc. (HGSI) and Eli Lilly and Co. Adimab initiated three new research collaborations for the use of its antibody discovery platform technology Financial terms were not disclosed Advanced Cell Technology Inc. (OTC BB:ACTC) Roslin Cells Ltd
Biotech Products Approved in 2013 | Biotech Products Approved 1982-2012 BIOTECH PRODUCTS 2013 Company Product Marketer Indication (U.S. Approval Date; Month/Day) Theravance Inc. Breo Ellipta GlaxoSmithKline plc Chronic obstructive pulmonary disease (5/13) Genentech Inc. Actemra Genentech Inc. Polyarticular juvenile idiopathic arthritis (5/1) Raptor Pharmaceutical Corp. Procysbi Raptor Pharmaceutical Corp. Nephropathic cystinosis (5/1) Sucampo Pharmaceuticals